Respiratory Health Diagnostic Seeks New Partner As RB Deal Aborted
Executive Summary
Australia's ResApp has terminated a deal with RB to bring to market a smartphone app to identify different respiratory conditions. Previously, Sanofi and ResApp failed to agree a deal for the technology.
You may also be interested in...
RB Coughs Up For Digital Diagnostic Development
Reckitt will work with former Sanofi partner ResApp to develop a consumer app which can diagnose common respiratory issues. The partnership represents RB's latest move into the digital space for its Health business.
Sanofi Strikes Deal To Develop Respiratory Health App
Sanofi Consumer Healthcare is working with digital health firm ResApp to develop a mobile application which consumers can use to diagnose and manage respiratory illnesses. Such a tool has the potential to support novel Rx-to-OTC switch applications in future.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.